Investors & Funding
AbilityPharma shareholders include the venture capital firms Inveready, CTI Life Sciences Fund, FiTalent and SODENA, private investors and the founders of the company.
This company is capitalized by Innvierte, an investment program of CDTI, E.P.E. and the European Innovation Council Fund (EIC Fund)
This company is capitalized by Innvierte, an investment program of CDTI, E.P.E. and the European Innovation Council Fund (EIC Fund)
The company has obtained grants and soft loans from high level public institutions:
- NEBT grant from ACCIÓ, Government of Catalonia.
- Technological Innovation Nuclei grant from ACCIÓ, Government of Catalonia.
- PID soft loan from CDTI, Government of Spain.
- Innoglobal from CDTI, Government of Spain.
- Innocash from Fundación Genoma España, Government of Spain.
- ENISA (National Innovation Company), Ministry of Industry, Energy and Tourism, Government of Spain.
- Investment Readiness program from ACC1Ó, Government of Catalonia.
- Torres-Quevedo grants from MINECO, Government of Spain.
- International Talent grant from Biocat (Bioregion Catalonia), Government of Catalonia.
- Inncorpora soft loan from the Ministry of Economy and Competitivity, Government of Spain.
- Innpacto soft loan from the Ministry of Economy and Competitivity, Government of Spain.
- Retos soft loan from the Ministry of Economy and Competitivity, Government of Spain.
- Proyectos de Colaboración público-privada from the Ministry of Science and Innovation MCIN/AEI, Goverment of Spain and the European Union NextGenerationEU/ PRTR
- Proyectos I+D+i en «líneas estratégicas» from the Ministry of Science and Innovation MCIN/AEI, Goverment of Spain, and the European Union NextGenerationEU/ PRTR
 |
 |
 |
|
|
 |
 |
 |
|
 |
The Ministry of Science and Innovation MCIN/AEI, Goverment of Spain, and the European Union NextGenerationEU/ PRTR have granted Ability Pharmaceuticals with a soft-loan in the Proyectos de Colaboración público-privada Program /10.13039/501100011033 entitled "Tratamiento innovador con ABTL0812 para el cancer pancreático metastático: acortando los tiempos para su aprobación - INNOPANC" with ref. CPP2021-009064. 2021.
The Ministry of Science and Innovation MCIN/AEI, Goverment of Spain, and the European Union NextGenerationEU/ PRTR have granted Ability Pharmaceuticals with a soft-loan in the Proyectos I+D+i en «líneas estratégicas» Program /10.13039/501100011033 entitled "Investigación de los efectos inmumoduladores de ABTL0812, un compuesto antitumoral activador de autofagia en fase clínica 2, e identificación de nuevos compuestos inmunoterapéuticos antitumorales basados en la autofagia" with ref. PLEC2022-009428. 2021.
Ability Pharmaceuticals participates in the projects "Development of new cancer therapies with high efficiency and specificity and low oral toxicity" and "Development of new financed by the call Retos-Colaboración del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, with the dossier numbers: RTC-2014-1532-1 i RTC -2014-2589-1 respectively.
Ability Pharmaceuticals participates in the project "New therapeutic approaches based on derivatives of essential fatty acids targeted to unmet needs in oncological and neurological diseases" funded by the INNPACTO call of the Spanish Research Program (MINECO) with dossier number IPT- 2012-0614-010000.
The project called "Clinical Investigation of ABTL0812 in combination with chemotherapy in non-small cell lung cancer and identification of associated biomarkers", has been subsidized by the CDTI and supported by the Ministry of Economy, Industry and Competitiveness, under the file number INNO-20171061 .
Ability Pharmaceuticals has received grants for recruitment : Torres Quevedo (PTQ-11-04900, PTQ-12-05453), Inncorpora (INC-TU-2012-2617) and Emplea (EMP-2015-4578 -2015 and EMP-2015-4569).
The Ministry of Science, Innovation and Universities, within the State Plan for Scientific and Technical Research and Innovation 2013-2016, granted assistance to the project "NEW STRATEGIES TO INCREASE EFFECTIVENESS OF TREATMENTS WITH ABTL0812" led by Ability Pharmaceuticals SL with file number RTC -2017-6261-1.
This project has been funded by the Ministry of Science, Innovation and Universities within the RETOS-COLLABORATION Subprogram, Call 2017.
The project is co-financed by the European Union with the aim of promoting technological development, innovation and quality research.
LATEST NEWS
05.06.2025
Press Release
AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer + info
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
